Back to top
more

Adicet Bio (ACET)

(Delayed Data from NSDQ)

$1.05 USD

1.05
947,144

-0.09 (-7.89%)

Updated Nov 14, 2024 04:00 PM ET

After-Market: $1.06 +0.01 (0.95%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 28% (71 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Down -53.98% in 4 Weeks, Here's Why You Should You Buy the Dip in Adicet Bio, Inc. (ACET)

by Zacks Equity Research

Adicet Bio, Inc. (ACET) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Sweta Killa headshot

5 Stocks to Pop Surprise Returns From Secret Santa

by Sweta Killa

Adicet Bio (ACET), Enfusion (ENFN), Dillard's (DDS), First BanCorp. (FBP) and Hillenbrand (HI) could bring gifts of surprise returns from Secret Santa.

Adicet Bio, Inc. (ACET) Loses 47% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

by Zacks Equity Research

Adicet Bio, Inc. (ACET) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Is Adicet Bio (ACET) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Adicet Bio, Inc. (ACET) and Merck (MRK) have performed compared to their sector so far this year.

What Makes Adicet Bio, Inc. (ACET) a Good Fit for 'Trend Investing'

by Zacks Equity Research

Adicet Bio, Inc. (ACET) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

Wall Street Analysts Think Adicet Bio, Inc. (ACET) Could Surge 72%: Read This Before Placing a Bet

by Zacks Equity Research

The mean of analysts' price targets for Adicet Bio, Inc. (ACET) points to a 71.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Wall Street Analysts See a 39% Upside in Adicet Bio, Inc. (ACET): Can the Stock Really Move This High?

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 38.7% in Adicet Bio, Inc. (ACET). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Is Adicet Bio (ACET) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Adicet Bio, Inc. (ACET) and RxSight, Inc. (RXST) have performed compared to their sector so far this year.

Adicet Bio, Inc. (ACET) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

Adicet Bio, Inc. (ACET) delivered earnings and revenue surprises of 5.36% and 100%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Karuna Therapeutics, Inc. (KRTX) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

Karuna Therapeutics, Inc. (KRTX) delivered earnings and revenue surprises of -19.60% and 99.19%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Adicet Bio, Inc. (ACET) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Adicet Bio, Inc. (ACET) delivered earnings and revenue surprises of -24.44% and 100%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Agenus (AGEN) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Agenus (AGEN) delivered earnings and revenue surprises of 26.09% and 11.93%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Adicet Bio, Inc. (ACET) Is a Great Choice for "Trend" Investors, Here's Why

by Zacks Equity Research

Adicet Bio, Inc. (ACET) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

Has Adicet Bio (ACET) Outpaced Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Adicet Bio, Inc. (ACET) and Catalyst Biosciences, Inc. (CBIO) have performed compared to their sector so far this year.

X4 Pharmaceuticals (XFOR) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

X4 Pharmaceuticals (XFOR) delivered earnings and revenue surprises of -16.13% and 100%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Clearside Biomedical, Inc. (CLSD) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Clearside Biomedical, Inc. (CLSD) delivered earnings and revenue surprises of -333.33% and 96.17%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Biohaven Pharmaceutical Holding Company Ltd. (BHVN) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Biohaven Pharmaceutical Holding Company Ltd. (BHVN) delivered earnings and revenue surprises of -17.86% and 70.40%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Pliant Therapeutics, Inc. (PLRX) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Pliant Therapeutics, Inc. (PLRX) delivered earnings and revenue surprises of -1.30% and 12.35%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Novavax (NVAX) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

On Novavax's (NVAX) first-quarter earnings call, investor focus is likely to be on the sales figures of its COVID-19 vaccine.

Vertex (VRTX) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

On Vertex Pharmaceuticals' (VRTX) Q1 earnings call, investors are most likely to focus on the sales performance of its triple combo CF drug Trikafta/Kaftrio and updates on the non-CF pipeline.

Adicet Bio, Inc. (ACET) Surges 6.8%: Is This an Indication of Further Gains?

by Zacks Equity Research

Adicet Bio, Inc. (ACET) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Assertio (ASRT) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

On Assertio Holdings' (ASRT) Q1 earnings call, investors will focus on the sales performance of its marketed products.

Adicet Bio, Inc. (ACET) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Adicet Bio, Inc. (ACET) delivered earnings and revenue surprises of -6.82% and 17.59%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Syros Pharmaceuticals, Inc. (SYRS) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Syros Pharmaceuticals, Inc. (SYRS) delivered earnings and revenue surprises of 4.55% and 38.09%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Is a Surprise Coming for Adicet Bio (ACET) This Earnings Season?

by Zacks Equity Research

Adicet Bio (ACET) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.